vs
マトソン（MATX）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
マトソンの直近四半期売上が大きい（$851.9M vs $790.2M、UNITED THERAPEUTICS Corpの約1.1倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 16.8%、差は29.3%）。UNITED THERAPEUTICS Corpの前年同期比売上増加率が高い（7.4% vs -4.3%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $42.2M）。過去8四半期でマトソンの売上複合成長率が高い（8.6% vs 8.0%）
マトソン社（Matson, Inc.）は米国の海運サービス企業で、ハワイ州ホノルルに本社を置き、1882年に創業した。子会社のマトソン・ナビゲーション・カンパニーは、ハワイ、アラスカ、グアム、ミクロネシア、太平洋諸島、中国、日本を対象に環太平洋の海運サービスを提供している。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
MATX vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $851.9M | $790.2M |
| 純利益 | $143.1M | $364.3M |
| 粗利率 | — | 86.9% |
| 営業利益率 | 16.9% | 45.1% |
| 純利益率 | 16.8% | 46.1% |
| 売上前年比 | -4.3% | 7.4% |
| 純利益前年比 | 11.8% | 20.9% |
| EPS（希薄化後） | $4.47 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $851.9M | $790.2M | ||
| Q3 25 | $880.1M | $799.5M | ||
| Q2 25 | $830.5M | $798.6M | ||
| Q1 25 | $782.0M | $794.4M | ||
| Q4 24 | $890.3M | $735.9M | ||
| Q3 24 | $962.0M | $748.9M | ||
| Q2 24 | $847.4M | $714.9M | ||
| Q1 24 | $722.1M | $677.7M |
| Q4 25 | $143.1M | $364.3M | ||
| Q3 25 | $134.7M | $338.7M | ||
| Q2 25 | $94.7M | $309.5M | ||
| Q1 25 | $72.3M | $322.2M | ||
| Q4 24 | $128.0M | $301.3M | ||
| Q3 24 | $199.1M | $309.1M | ||
| Q2 24 | $113.2M | $278.1M | ||
| Q1 24 | $36.1M | $306.6M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 16.9% | 45.1% | ||
| Q3 25 | 18.3% | 48.6% | ||
| Q2 25 | 13.6% | 45.6% | ||
| Q1 25 | 10.5% | 48.2% | ||
| Q4 24 | 16.6% | 48.6% | ||
| Q3 24 | 25.2% | 45.8% | ||
| Q2 24 | 14.7% | 44.7% | ||
| Q1 24 | 5.1% | 52.6% |
| Q4 25 | 16.8% | 46.1% | ||
| Q3 25 | 15.3% | 42.4% | ||
| Q2 25 | 11.4% | 38.8% | ||
| Q1 25 | 9.2% | 40.6% | ||
| Q4 24 | 14.4% | 40.9% | ||
| Q3 24 | 20.7% | 41.3% | ||
| Q2 24 | 13.4% | 38.9% | ||
| Q1 24 | 5.0% | 45.2% |
| Q4 25 | $4.47 | $7.66 | ||
| Q3 25 | $4.24 | $7.16 | ||
| Q2 25 | $2.92 | $6.41 | ||
| Q1 25 | $2.18 | $6.63 | ||
| Q4 24 | $3.69 | $6.23 | ||
| Q3 24 | $5.89 | $6.39 | ||
| Q2 24 | $3.31 | $5.85 | ||
| Q1 24 | $1.04 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $141.9M | $2.9B |
| 総負債低いほど良い | $361.2M | — |
| 株主資本純資産 | $2.8B | $7.1B |
| 総資産 | $4.6B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.13× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $141.9M | $2.9B | ||
| Q3 25 | $92.7M | $2.8B | ||
| Q2 25 | $59.1M | $3.0B | ||
| Q1 25 | $122.0M | $3.3B | ||
| Q4 24 | $266.8M | $3.3B | ||
| Q3 24 | $270.3M | $3.3B | ||
| Q2 24 | $168.2M | $3.0B | ||
| Q1 24 | $25.9M | $2.7B |
| Q4 25 | $361.2M | — | ||
| Q3 25 | $370.9M | — | ||
| Q2 25 | $341.3M | — | ||
| Q1 25 | $351.1M | — | ||
| Q4 24 | $361.2M | — | ||
| Q3 24 | $370.9M | — | ||
| Q2 24 | $381.0M | — | ||
| Q1 24 | $390.8M | — |
| Q4 25 | $2.8B | $7.1B | ||
| Q3 25 | $2.7B | $6.6B | ||
| Q2 25 | $2.6B | $7.2B | ||
| Q1 25 | $2.6B | $6.8B | ||
| Q4 24 | $2.7B | $6.4B | ||
| Q3 24 | $2.6B | $6.1B | ||
| Q2 24 | $2.4B | $5.7B | ||
| Q1 24 | $2.4B | $5.3B |
| Q4 25 | $4.6B | $7.9B | ||
| Q3 25 | $4.6B | $7.4B | ||
| Q2 25 | $4.5B | $7.9B | ||
| Q1 25 | $4.5B | $7.7B | ||
| Q4 24 | $4.6B | $7.4B | ||
| Q3 24 | $4.4B | $7.1B | ||
| Q2 24 | $4.3B | $6.7B | ||
| Q1 24 | $4.2B | $6.5B |
| Q4 25 | 0.13× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $176.9M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $42.2M | $173.3M |
| FCFマージンFCF / 売上 | 5.0% | 21.9% |
| 設備投資強度設備投資 / 売上 | 15.8% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.24× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $153.7M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $176.9M | $346.2M | ||
| Q3 25 | $175.6M | $562.1M | ||
| Q2 25 | $105.6M | $191.7M | ||
| Q1 25 | $89.0M | $461.2M | ||
| Q4 24 | $174.7M | $341.2M | ||
| Q3 24 | $248.6M | $377.2M | ||
| Q2 24 | $307.9M | $232.2M | ||
| Q1 24 | $36.6M | $376.5M |
| Q4 25 | $42.2M | $173.3M | ||
| Q3 25 | $92.4M | $351.6M | ||
| Q2 25 | $19.3M | $129.5M | ||
| Q1 25 | $-200.0K | $386.3M | ||
| Q4 24 | $49.3M | $254.5M | ||
| Q3 24 | $189.0M | $300.7M | ||
| Q2 24 | $238.1M | $187.1M | ||
| Q1 24 | $-18.7M | $338.3M |
| Q4 25 | 5.0% | 21.9% | ||
| Q3 25 | 10.5% | 44.0% | ||
| Q2 25 | 2.3% | 16.2% | ||
| Q1 25 | -0.0% | 48.6% | ||
| Q4 24 | 5.5% | 34.6% | ||
| Q3 24 | 19.6% | 40.2% | ||
| Q2 24 | 28.1% | 26.2% | ||
| Q1 24 | -2.6% | 49.9% |
| Q4 25 | 15.8% | 21.9% | ||
| Q3 25 | 9.5% | 26.3% | ||
| Q2 25 | 10.4% | 7.8% | ||
| Q1 25 | 11.4% | 9.4% | ||
| Q4 24 | 14.1% | 11.8% | ||
| Q3 24 | 6.2% | 10.2% | ||
| Q2 24 | 8.2% | 6.3% | ||
| Q1 24 | 7.7% | 5.6% |
| Q4 25 | 1.24× | 0.95× | ||
| Q3 25 | 1.30× | 1.66× | ||
| Q2 25 | 1.12× | 0.62× | ||
| Q1 25 | 1.23× | 1.43× | ||
| Q4 24 | 1.36× | 1.13× | ||
| Q3 24 | 1.25× | 1.22× | ||
| Q2 24 | 2.72× | 0.83× | ||
| Q1 24 | 1.01× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MATX
| Ocean Transportation Segment | $704.2M | 83% |
| Logistics Services Segment | $147.7M | 17% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
